Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Actual-world therapy with the autologous anti-CD19 CAR T-cell remedy Yescarta (axicabtagene ciloleucel; axi-cel) demonstrated sturdy responses and a manageable security profile amongst...
Remedy with Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj; subcutaneous daratumumab) led to significant enhancements in each general survival and progression-free...